𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus

✍ Scribed by José M. Cuevas; Manuela Torres-Puente; Nuria Jiménez-Hernández; María A. Bracho; Inmaculada García-Robles; Fernando Carnicer; Juan del Olmo; Enrique Ortega; Fernando González-Candelas; Andrés Moya


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
368 KB
Volume
81
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Hepatitis C virus (HCV) presents several regions involved potentially in evading antiviral treatment and host immune system. Two regions, known as PKR‐BD and V3 domains, have been proposed to be involved in resistance to interferon. Additionally, hypervariable regions in the envelope E2 glycoprotein are also good candidates to participate in evasion from the immune system. In this study, we have used a cohort of 22 non‐responder patients to combined therapy (interferon alpha‐2a plus ribavirin) for which samples obtained just before initiation of therapy and after 6 or/and 12 months of treatment were available. A range of 25–100 clones per patient, genome region and time sample were obtained. The predominant amino acid sequences for each time sample and patient were determined. Next, the sequences of the PKR‐BD and V3 domains and the hypervariable regions from different time samples were compared for each patient. The highest levels of variability were detected at the three hypervariable regions of the E2 protein and, to a lower extent, at the V3 domain of the NS5A protein. However, no clear patterns of adaptation to the host immune system or to antiviral treatment were detected. In summary, although high levels of variability are correlated to viral adaptive response, antiviral treatment does not seem to promote convergent adaptive changes. Consequently, other regions must be involved in evasion strategies likely based on a combination of multiple mechanisms, in which pools of changes along the HCV genome could confer viruses the ability to overcome strong selective pressures. J. Med. Virol. 81:650–656, 2009 © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Predictors of viral kinetics to peginter
✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor of treatment efficacy, but the underlying mechanisms of the different viral kinetics to treatment are sti

Genetic variability of hepatitis C virus
✍ I. Vuillermoz; E. Khattab; E. Sablon; I. Ottevaere; D. Durantel; C. Vieux; C. Tr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 2 views

## Abstract Little is known about hepatitis C virus (HCV) breakthrough during antiviral therapy, although it would help in understanding HCV resistance to current antiviral treatments. To analyse the implication of virological factors and the vigour of humoral immune responses in this phenomenon, w

Efficacy of low-dose intermittent interf
✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec

Functional impairment of dendritic cells
✍ Cheng-Chao Liang; Chen-Hua Liu; Yu-Li Lin; Chun-Jen Liu; Bor-Luen Chiang; Jia-Ho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 631 KB

## Abstract Although chronic hepatitis C patients have a lower frequency and functions of dendritic cells (DCs) than healthy subjects, little is known about the serial changes in frequency and functions of DCs following anti‐viral treatment and the relationship with treatment outcomes. Twenty patie

A mutation in the interferon sensitivity
✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon